Design and in silico screening of novel isoniazid-based Schiff base derivatives followed by synthesis and biological evaluation of the lead compound against Mycobacterium tuberculosis H37Rv

The development of new antitubercular agents is critically needed due to the rising incidence of drug-resistant Mycobacterium tuberculosis . In the present study, a series of isoniazid-based Schiff base derivatives was designed and evaluated using an integrated in silico approach. A virtual library comprising 30 compounds was designed and systematically screened. Based on an integrated computational screening strategy involving drug-likeness evaluation, absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling, Prediction of Activity Spectra for Substances (PASS) analysis, and molecular docking, the highest-ranked lead compound (SLB-5) was selected for synthesis, structural characterization, and biological evaluation. Molecular docking was performed against enoyl-acyl carrier protein reductase (InhA) of M. tuberculosis (PDB ID: 6EP8), identifying compounds with favorable predicted binding affinities ranging from − 8.7 to − 9.5 kcal/mol, which were more favorable than the docking score of isoniazid (− 5.8 kcal/mol). The selected lead compound, SLB-5, was synthesized via Schiff base condensation and characterized using Fourier-transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance (¹H NMR), and high-resolution mass spectrometry (HRMS), confirming the formation of the azomethine (–C=N–) linkage. The antitubercular activity of SLB-5 was evaluated against M. tuberculosis H37Rv using the Alamar Blue assay, demonstrating concentration-dependent growth inhibition. Overall, the findings suggest that isoniazid-based Schiff base derivatives represent a promising scaffold for the development of new antitubercular agents. The study demonstrates the utility of an integrated computational screening workflow for prioritizing lead compounds for synthesis and biological evaluation, with SLB-5 emerging as a promising candidate for further investigation.

Authors

Institutions

Publication Details

Journal
Discover Chemistry.
Published
2026-09-16
DOI
https://doi.org/10.1007/s44371-026-00909-w
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Design and in silico screening of novel isoniazid-based Schiff base derivatives followed by synthesis and biological evaluation of the lead compound against Mycobacterium tuberculosis H37Rv

Pallavi M. Patil, Shivani L. Bhuse, Rajat R. Durbule
Discover Chemistry.
Tuberculosis Research and Epidemiology
article

Design and in silico screening of novel isoniazid-based Schiff base derivatives followed by synthesis and biological evaluation of the lead compound against Mycobacterium tuberculosis H37Rv

Pallavi M. Patil, Shivani L. Bhuse, Rajat R. Durbule
article en

Abstract

The development of new antitubercular agents is critically needed due to the rising incidence of drug-resistant Mycobacterium tuberculosis . In the present study, a series of isoniazid-based Schiff base derivatives was designed and evaluated using an integrated in silico approach. A virtual library comprising 30 compounds was designed and systematically screened. Based on an integrated computational screening strategy involving drug-likeness evaluation, absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling, Prediction of Activity Spectra for Substances (PASS) analysis, and molecular docking, the highest-ranked lead compound (SLB-5) was selected for synthesis, structural characterization, and biological evaluation. Molecular docking was performed against enoyl-acyl carrier protein reductase (InhA) of M. tuberculosis (PDB ID: 6EP8), identifying compounds with favorable predicted binding affinities ranging from − 8.7 to − 9.5 kcal/mol, which were more favorable than the docking score of isoniazid (− 5.8 kcal/mol). The selected lead compound, SLB-5, was synthesized via Schiff base condensation and characterized using Fourier-transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance (¹H NMR), and high-resolution mass spectrometry (HRMS), confirming the formation of the azomethine (–C=N–) linkage. The antitubercular activity of SLB-5 was evaluated against M. tuberculosis H37Rv using the Alamar Blue assay, demonstrating concentration-dependent growth inhibition. Overall, the findings suggest that isoniazid-based Schiff base derivatives represent a promising scaffold for the development of new antitubercular agents. The study demonstrates the utility of an integrated computational screening workflow for prioritizing lead compounds for synthesis and biological evaluation, with SLB-5 emerging as a promising candidate for further investigation.

Discover Chemistry.Vol. 3(1)
Savitribai Phule Pune University (IN)
Savitribai Phule Pune University
Good health and well-being
Openalex Percentile: Top 11%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.